Every figure on this page comes from documents Bio-Rad Laboratories, Inc. Class A Common Stock filed with the exchange, and each one was checked against the document itself before publication. What could not be verified is not here.
| Quarter | Revenue | YoY | Net profit | YoY | Net margin |
|---|---|---|---|---|---|
| Jun 2026 | $651 mn | -0.1% | $371 mn | +16.9% | 57.1% |
| Mar 2026 | $592 mn | +1.1% | $-527 mn | -923.6% | -89.0% |
| Dec 2025 | $693 mn | +3.9% | $720 mn | +200.6% | 103.9% |
| Sep 2025 | $653 mn | +0.5% | $-342 mn | -152.3% | -52.4% |
| Jun 2025 | $652 mn | +2.1% | $318 mn | +114.7% | 48.8% |
| Mar 2025 | $585 mn | -4.2% | $64 mn | -83.3% | 10.9% |
Watch it, and each morning it files something you get the checked numbers, the sources, and red-flag alerts when the quiet numbers move — pledges, ratings, resignations. Ask by name any evening and it is read overnight.
Start free — first week on us →Data from documents filed with the exchanges, checked against the documents themselves. This page states facts and is not investment advice or a recommendation. Investment in securities markets is subject to market risks. Research on this site is produced with substantial use of AI and verified against filed documents. Terms, disclosures and grievances